The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 26 June 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 384K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitani, A.
Right arrow Articles by Strober, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitani, A.
Right arrow Articles by Strober, W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/7/41/ $5.00
The Journal of Experimental Medicine, Volume 192, Number 1, July 3, 2000 41-52


Original Article

Treatment of Experimental (Trinitrobenzene Sulfonic Acid) Colitis by Intranasal Administration of Transforming Growth Factor (TGF)-ß1 Plasmid: TGF-ß1–mediated Suppression of T Helper Cell Type 1 Response Occurs by Interleukin (IL)-10 Induction and IL-12 Receptor ß2 Chain Downregulation

Atsushi Kitania, Ivan J. Fussa, Kazuhiko Nakamuraa, Owen M. Schwartzb, Takashi Usuia, and Warren Strobera
a Mucosal Immunity Section, Laboratory of Clinical Investigation
b Biological Imaging Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892

Correspondence to: Warren Strober, Bldg. 10, Rm. 11N238, 10 Center Dr., Bethesda, MD 20892. Tel:301-496-6810 Fax:301-402-2240 E-mail:wstrober{at}niaid.nih.gov.

In this study, we show that a single intranasal dose of a plasmid encoding active transforming growth factor ß1 (pCMV-TGF-ß1) prevents the development of T helper cell type 1 (Th1)-mediated experimental colitis induced by the haptenating reagent, 2,4,6-trinitrobenzene sulfonic acid (TNBS). In addition, such plasmid administration abrogates TNBS colitis after it has been established, whereas, in contrast, intraperitoneal administration of rTGF-ß1 protein does not have this effect. Intranasal pCMV-TGF-ß1 administration leads to the expression of TGF-ß1 mRNA in the intestinal lamina propria and spleen for 2 wk, as well as the appearance of TGF-ß1–producing T cells and macrophages in these tissues, and is not associated with the appearances of fibrosis. These cells cause marked suppression of interleukin (IL)-12 and interferon (IFN)-{gamma} production and enhancement of IL-10 production; in addition, they inhibit IL-12 receptor ß2 (IL-12Rß2) chain expression. Coadministration of anti–IL-10 at the time of pCMV-TGF-ß1 administration prevents the enhancement of IL-10 production and reverses the suppression of IL-12 but not IFN-{gamma} secretion. However, anti–IL-10 leads to increased tumor necrosis factor {alpha} production, especially in established colitis. Taken together, these studies show that TGF-ß1 inhibition of a Th1-mediated colitis is due to: (a) suppression of IL-12 secretion by IL-10 induction and (b) inhibition of IL-12 signaling via downregulation of IL-12Rß2 chain expression. In addition, TGF-ß1 may also have an inhibitory effect on IFN-{gamma} transcription.

Key Words: delivery, hapten, interferon {gamma}, tumor necrosis factor {alpha}, ß-galactosidase


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS